Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 55,037,721 |
|
|||||
| News | - | ||||||
| Day High | 7.615 | Low High |
|||||
| Day Low | 5.53 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Altimmune Inc | ALT | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 1.73 | 33.46% | 6.90 | 19:53:47 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 5.71 | 5.53 | 7.615 | 6.88 | 5.17 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 211,422 | 55,037,721 | $ 6.78 | $ 373,125,874 | - | 2.09 - 17.17 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:53:48 | 5 | $ 6.9597 | USD |
Altimmune (ALT) Options Flow Summary
Altimmune Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 370.19M | 53.73M | - | -68k | -84.71M | -1.58 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Altimmune News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ALT Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.11 | 7.615 | 3.08 | 4.04 | 35,956,881 | 3.79 | 121.86% |
| 1 Month | 2.69 | 7.615 | 2.315 | 3.91 | 10,410,550 | 4.21 | 156.51% |
| 3 Months | 2.64 | 7.615 | 2.09 | 3.64 | 4,194,391 | 4.26 | 161.36% |
| 6 Months | 4.27 | 7.615 | 2.09 | 3.58 | 2,814,624 | 2.63 | 61.59% |
| 1 Year | 10.90 | 17.17 | 2.09 | 5.49 | 2,304,976 | -4.00 | -36.7% |
| 3 Years | 12.29 | 24.61 | 2.09 | 9.51 | 1,747,978 | -5.39 | -43.86% |
| 5 Years | 3.17 | 35.10 | 1.45 | 10.03 | 1,630,138 | 3.73 | 117.67% |
Altimmune Description
| Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH (non-alcoholic steatohepatitis). In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B virus (HBV). |
